Founded in 2005, InspireMD, Inc. (NSPR) is committed to developing advanced medical technologies designed to improve the lives of patients worldwide. Informally known as 'Inspire,' this Massachusetts-based medical device company excels in creating proprietary MicroNet™ stent platform technology for use in various vascular applications. Known for innovation, the company's landmark products, CGuard™ EPS and MGuard™ Prime, are explicitly engineered to address the unmet needs in the treatment of complex vascular diseases.
Notably, CGuard™ EPS is an embolic prevention stent system designed to prevent stroke caused by carotid artery disease. This device has an innovative design which incorporates a stent overlaid with a MicroNet™ mesh. The unique meshwork reduces stroke risk by preventing plaque detachment during or after the procedure. Meanwhile, MGuard™ Prime is a coronary stent system designed to reduce the risk of blood clot formation and subsequent heart attacks.
InspireMD's development and product line are grounded in the rigorous science and clinical research. These products have been proven effective in various clinical studies, earning the CE mark in Europe and recognition from the medical community. However, these procedures are still pending approval by the U.S. Food and Drug Administration.
The company's ticker symbol is NSPR, and it trades on the New York Stock Exchange. Despite various challenges over the years, including looming regulatory hurdles and market competition, InspireMD continues to push for innovation. The company is ever-focused on addressing the significant, unserved need in the cardiovascular market. Maintaining patient-safety as priority, it continues to strive to devise effective solutions for vascular complications.
InspireMD boasts an experienced leadership team that continually drives the company toward growth and success. The company's dedication to alleviating the burden of vascular diseases through quality, innovative medical technologies has cemented its reputation as a leading player in the medical device industry. Despite only being in operation for just over a decade and half, InspireMD's commitment to improving patient outcomes is evident, making them a significant entity in the health care technology field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
InspireMD has amended its Series J and K warrants, setting a new exercise price of $0.7674. These changes could generate up to $11 million in gross proceeds if all warrants are fully exercised. A key update is the linking of the expiration date to FDA approval for CGuard Prime 80 cm, with the new deadline being May 15, 2028, or earlier based on FDA announcement.
InspireMD's Q2 2026 earnings call revealed a company navigating significant financial challenges due to a voluntary product recall, resulting in a negative gross margin, wider net loss, and substantial cash burn. Despite these issues, the company reported strong international growth and positive U.S. regulatory progress for its CGuard products. InspireMD is implementing cost-cutting measures and focusing on regulatory approvals and a commercial relaunch to restore liquidity and return to growth.
InspireMD (NSPR) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This upgrade suggests an improvement in the company's underlying business and future earnings potential, which historically correlates with favorable stock price movement. The Zacks system identifies NSPR as a solid investment candidate, placing it in the top 20% of Zacks-covered stocks based on estimate revisions.
InspireMD, Inc. (NSPR) reported its Q2 2026 financial results, with a narrower loss per share of -$0.17, beating analyst expectations by 15%, and revenue of $1.8M, surpassing estimates by 28%. Despite a slight revenue decrease year-over-year, international markets showed strong growth. Wall Street analysts maintain a bullish outlook on the stock.
InspireMD, Inc. reported a narrower loss for Q2 2026, beating analyst expectations with a loss of $0.17 per share against an anticipated $0.20 loss. Revenue reached $1.8M, surpassing the $1.4M consensus, despite remaining flat year-over-year. International markets were a key driver, contributing $2.1M in revenue and reflecting strong adoption of the company's vascular treatment devices.